The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Omalizumab Monoclonal Antibody Biosimilars Market Research Report 2024
Synopsis
Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The global Omalizumab Monoclonal Antibody Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Omalizumab Monoclonal Antibody Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Omalizumab Monoclonal Antibody Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Omalizumab Monoclonal Antibody Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Omalizumab Monoclonal Antibody Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Monoclonal Antibody Biosimilars.
Report Scope
The Omalizumab Monoclonal Antibody Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Omalizumab Monoclonal Antibody Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omalizumab Monoclonal Antibody Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Omalizumab Monoclonal Antibody Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Omalizumab Monoclonal Antibody Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The global Omalizumab Monoclonal Antibody Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Omalizumab Monoclonal Antibody Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Omalizumab Monoclonal Antibody Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Omalizumab Monoclonal Antibody Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Omalizumab Monoclonal Antibody Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Monoclonal Antibody Biosimilars.
Report Scope
The Omalizumab Monoclonal Antibody Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Omalizumab Monoclonal Antibody Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omalizumab Monoclonal Antibody Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Omalizumab Monoclonal Antibody Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Omalizumab Monoclonal Antibody Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Omalizumab Monoclonal Antibody Biosimilars Market Overview
1.1 Product Overview and Scope of Omalizumab Monoclonal Antibody Biosimilars
1.2 Omalizumab Monoclonal Antibody Biosimilars Segment by Type
1.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Omalizumab Monoclonal Antibody Biosimilars Segment by Application
1.3.1 Global Omalizumab Monoclonal Antibody Biosimilars Market Value by Application: (2024-2030)
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Global Omalizumab Monoclonal Antibody Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue 2019-2030
1.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales 2019-2030
1.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Omalizumab Monoclonal Antibody Biosimilars Market Competition by Manufacturers
2.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Omalizumab Monoclonal Antibody Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Omalizumab Monoclonal Antibody Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Omalizumab Monoclonal Antibody Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Omalizumab Monoclonal Antibody Biosimilars, Product Type & Application
2.7 Omalizumab Monoclonal Antibody Biosimilars Market Competitive Situation and Trends
2.7.1 Omalizumab Monoclonal Antibody Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Omalizumab Monoclonal Antibody Biosimilars Players Market Share by Revenue
2.7.3 Global Omalizumab Monoclonal Antibody Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Omalizumab Monoclonal Antibody Biosimilars Retrospective Market Scenario by Region
3.1 Global Omalizumab Monoclonal Antibody Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Omalizumab Monoclonal Antibody Biosimilars Global Omalizumab Monoclonal Antibody Biosimilars Sales by Region: 2019-2030
3.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Region: 2019-2024
3.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Region: 2025-2030
3.3 Global Omalizumab Monoclonal Antibody Biosimilars Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Region: 2025-2030
3.4 North America Omalizumab Monoclonal Antibody Biosimilars Market Facts & Figures by Country
3.4.1 North America Omalizumab Monoclonal Antibody Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2030)
3.4.3 North America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Omalizumab Monoclonal Antibody Biosimilars Market Facts & Figures by Country
3.5.1 Europe Omalizumab Monoclonal Antibody Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Omalizumab Monoclonal Antibody Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Omalizumab Monoclonal Antibody Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Omalizumab Monoclonal Antibody Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Omalizumab Monoclonal Antibody Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2019-2030)
4.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2019-2024)
4.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2025-2030)
4.1.3 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Omalizumab Monoclonal Antibody Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2019-2030)
5.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2019-2024)
5.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2025-2030)
5.1.3 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Omalizumab Monoclonal Antibody Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Glenmark Pharmaceuticals
6.3.1 Glenmark Pharmaceuticals Corporation Information
6.3.2 Glenmark Pharmaceuticals Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.4 Selexis
6.4.1 Selexis Corporation Information
6.4.2 Selexis Description and Business Overview
6.4.3 Selexis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Selexis Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.4.5 Selexis Recent Developments/Updates
6.5 Generium
6.5.1 Generium Corporation Information
6.5.2 Generium Description and Business Overview
6.5.3 Generium Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Generium Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.5.5 Generium Recent Developments/Updates
6.6 CuraTeQ
6.6.1 CuraTeQ Corporation Information
6.6.2 CuraTeQ Description and Business Overview
6.6.3 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.6.5 CuraTeQ Recent Developments/Updates
6.7 Celltrion Healthcare
6.6.1 Celltrion Healthcare Corporation Information
6.6.2 Celltrion Healthcare Description and Business Overview
6.6.3 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.7.5 Celltrion Healthcare Recent Developments/Updates
6.8 Alvotech
6.8.1 Alvotech Corporation Information
6.8.2 Alvotech Description and Business Overview
6.8.3 Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Alvotech Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.8.5 Alvotech Recent Developments/Updates
6.9 BiosanaPharma
6.9.1 BiosanaPharma Corporation Information
6.9.2 BiosanaPharma Description and Business Overview
6.9.3 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.9.5 BiosanaPharma Recent Developments/Updates
6.10 Mabpharm
6.10.1 Mabpharm Corporation Information
6.10.2 Mabpharm Description and Business Overview
6.10.3 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.10.5 Mabpharm Recent Developments/Updates
6.11 CSPC Pharmaceutical Group
6.11.1 CSPC Pharmaceutical Group Corporation Information
6.11.2 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Description and Business Overview
6.11.3 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.12 Biomabs
6.12.1 Biomabs Corporation Information
6.12.2 Biomabs Omalizumab Monoclonal Antibody Biosimilars Description and Business Overview
6.12.3 Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Biomabs Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.12.5 Biomabs Recent Developments/Updates
6.13 HisunPharm
6.13.1 HisunPharm Corporation Information
6.13.2 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Description and Business Overview
6.13.3 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.13.5 HisunPharm Recent Developments/Updates
6.14 Grand Pharm
6.14.1 Grand Pharm Corporation Information
6.14.2 Grand Pharm Omalizumab Monoclonal Antibody Biosimilars Description and Business Overview
6.14.3 Grand Pharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Grand Pharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolio
6.14.5 Grand Pharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Omalizumab Monoclonal Antibody Biosimilars Industry Chain Analysis
7.2 Omalizumab Monoclonal Antibody Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Omalizumab Monoclonal Antibody Biosimilars Production Mode & Process
7.4 Omalizumab Monoclonal Antibody Biosimilars Sales and Marketing
7.4.1 Omalizumab Monoclonal Antibody Biosimilars Sales Channels
7.4.2 Omalizumab Monoclonal Antibody Biosimilars Distributors
7.5 Omalizumab Monoclonal Antibody Biosimilars Customers
8 Omalizumab Monoclonal Antibody Biosimilars Market Dynamics
8.1 Omalizumab Monoclonal Antibody Biosimilars Industry Trends
8.2 Omalizumab Monoclonal Antibody Biosimilars Market Drivers
8.3 Omalizumab Monoclonal Antibody Biosimilars Market Challenges
8.4 Omalizumab Monoclonal Antibody Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Omalizumab Monoclonal Antibody Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Omalizumab Monoclonal Antibody Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Omalizumab Monoclonal Antibody Biosimilars Market Competitive Situation by Manufacturers in 2023
Table 4. Global Omalizumab Monoclonal Antibody Biosimilars Sales (Units) of Key Manufacturers (2019-2024)
Table 5. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Omalizumab Monoclonal Antibody Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Omalizumab Monoclonal Antibody Biosimilars Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Omalizumab Monoclonal Antibody Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Omalizumab Monoclonal Antibody Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Omalizumab Monoclonal Antibody Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Omalizumab Monoclonal Antibody Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Omalizumab Monoclonal Antibody Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Monoclonal Antibody Biosimilars as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Omalizumab Monoclonal Antibody Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2019-2024) & (Units)
Table 18. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region (2019-2024)
Table 19. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2025-2030) & (Units)
Table 20. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region (2025-2030)
Table 21. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Region (2019-2024)
Table 23. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Region (2025-2030)
Table 25. North America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2024) & (Units)
Table 27. North America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2025-2030) & (Units)
Table 28. North America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2024) & (Units)
Table 32. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2025-2030) & (Units)
Table 33. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2019-2024) & (Units)
Table 37. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2025-2030) & (Units)
Table 38. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2024) & (Units)
Table 42. Latin America Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2025-2030) & (Units)
Table 43. Latin America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2019-2024) & (Units)
Table 47. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2025-2030) & (Units)
Table 48. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Omalizumab Monoclonal Antibody Biosimilars Sales (Units) by Type (2019-2024)
Table 51. Global Omalizumab Monoclonal Antibody Biosimilars Sales (Units) by Type (2025-2030)
Table 52. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2019-2024)
Table 53. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2025-2030)
Table 54. Global Omalizumab Monoclonal Antibody Biosimilars Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Omalizumab Monoclonal Antibody Biosimilars Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2019-2024)
Table 57. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2025-2030)
Table 58. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Type (2019-2024)
Table 59. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Type (2025-2030)
Table 60. Global Omalizumab Monoclonal Antibody Biosimilars Sales (Units) by Application (2019-2024)
Table 61. Global Omalizumab Monoclonal Antibody Biosimilars Sales (Units) by Application (2025-2030)
Table 62. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2019-2024)
Table 63. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2025-2030)
Table 64. Global Omalizumab Monoclonal Antibody Biosimilars Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Omalizumab Monoclonal Antibody Biosimilars Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application (2019-2024)
Table 67. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application (2025-2030)
Table 68. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Application (2019-2024)
Table 69. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Application (2025-2030)
Table 70. Roche Corporation Information
Table 71. Roche Description and Business Overview
Table 72. Roche Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Roche Omalizumab Monoclonal Antibody Biosimilars Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Novartis Omalizumab Monoclonal Antibody Biosimilars Product
Table 79. Novartis Recent Developments/Updates
Table 80. Glenmark Pharmaceuticals Corporation Information
Table 81. Glenmark Pharmaceuticals Description and Business Overview
Table 82. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product
Table 84. Glenmark Pharmaceuticals Recent Developments/Updates
Table 85. Selexis Corporation Information
Table 86. Selexis Description and Business Overview
Table 87. Selexis Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Selexis Omalizumab Monoclonal Antibody Biosimilars Product
Table 89. Selexis Recent Developments/Updates
Table 90. Generium Corporation Information
Table 91. Generium Description and Business Overview
Table 92. Generium Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Generium Omalizumab Monoclonal Antibody Biosimilars Product
Table 94. Generium Recent Developments/Updates
Table 95. CuraTeQ Corporation Information
Table 96. CuraTeQ Description and Business Overview
Table 97. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product
Table 99. CuraTeQ Recent Developments/Updates
Table 100. Celltrion Healthcare Corporation Information
Table 101. Celltrion Healthcare Description and Business Overview
Table 102. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product
Table 104. Celltrion Healthcare Recent Developments/Updates
Table 105. Alvotech Corporation Information
Table 106. Alvotech Description and Business Overview
Table 107. Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Alvotech Omalizumab Monoclonal Antibody Biosimilars Product
Table 109. Alvotech Recent Developments/Updates
Table 110. BiosanaPharma Corporation Information
Table 111. BiosanaPharma Description and Business Overview
Table 112. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product
Table 114. BiosanaPharma Recent Developments/Updates
Table 115. Mabpharm Corporation Information
Table 116. Mabpharm Description and Business Overview
Table 117. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product
Table 119. Mabpharm Recent Developments/Updates
Table 120. CSPC Pharmaceutical Group Corporation Information
Table 121. CSPC Pharmaceutical Group Description and Business Overview
Table 122. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product
Table 124. CSPC Pharmaceutical Group Recent Developments/Updates
Table 125. Biomabs Corporation Information
Table 126. Biomabs Description and Business Overview
Table 127. Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Biomabs Omalizumab Monoclonal Antibody Biosimilars Product
Table 129. Biomabs Recent Developments/Updates
Table 130. HisunPharm Corporation Information
Table 131. HisunPharm Description and Business Overview
Table 132. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product
Table 134. HisunPharm Recent Developments/Updates
Table 135. Grand Pharm Corporation Information
Table 136. Grand Pharm Description and Business Overview
Table 137. Grand Pharm Omalizumab Monoclonal Antibody Biosimilars Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Grand Pharm Omalizumab Monoclonal Antibody Biosimilars Product
Table 139. Grand Pharm Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Omalizumab Monoclonal Antibody Biosimilars Distributors List
Table 143. Omalizumab Monoclonal Antibody Biosimilars Customers List
Table 144. Omalizumab Monoclonal Antibody Biosimilars Market Trends
Table 145. Omalizumab Monoclonal Antibody Biosimilars Market Drivers
Table 146. Omalizumab Monoclonal Antibody Biosimilars Market Challenges
Table 147. Omalizumab Monoclonal Antibody Biosimilars Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Omalizumab Monoclonal Antibody Biosimilars
Figure 2. Global Omalizumab Monoclonal Antibody Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Omalizumab Monoclonal Antibody Biosimilars Market Share by Type in 2023 & 2030
Figure 4. 150 mg/mL Product Picture
Figure 5. 75 mg/0.5 mL Product Picture
Figure 6. Global Omalizumab Monoclonal Antibody Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Omalizumab Monoclonal Antibody Biosimilars Market Share by Application in 2023 & 2030
Figure 8. Persistent Asthma
Figure 9. Nasal Polyps
Figure 10. Chronic Idiopathic Urticaria
Figure 11. Global Omalizumab Monoclonal Antibody Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Omalizumab Monoclonal Antibody Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 13. Global Omalizumab Monoclonal Antibody Biosimilars Sales (2019-2030) & (Units)
Figure 14. Global Omalizumab Monoclonal Antibody Biosimilars Average Price (USD/Unit) & (2019-2030)
Figure 15. Omalizumab Monoclonal Antibody Biosimilars Report Years Considered
Figure 16. Omalizumab Monoclonal Antibody Biosimilars Sales Share by Manufacturers in 2023
Figure 17. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Omalizumab Monoclonal Antibody Biosimilars Players: Market Share by Revenue in 2023
Figure 19. Omalizumab Monoclonal Antibody Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Omalizumab Monoclonal Antibody Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2019-2030)
Figure 22. North America Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2019-2030)
Figure 23. United States Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2019-2030)
Figure 26. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2019-2030)
Figure 27. Germany Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Region (2019-2030)
Figure 34. China Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2019-2030)
Figure 42. Latin America Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2019-2030)
Figure 43. Mexico Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Brazil Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Argentina Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2019-2030)
Figure 47. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2019-2030)
Figure 48. Turkey Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. UAE Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Global Sales Market Share of Omalizumab Monoclonal Antibody Biosimilars by Type (2019-2030)
Figure 52. Global Revenue Market Share of Omalizumab Monoclonal Antibody Biosimilars by Type (2019-2030)
Figure 53. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Type (2019-2030)
Figure 54. Global Sales Market Share of Omalizumab Monoclonal Antibody Biosimilars by Application (2019-2030)
Figure 55. Global Revenue Market Share of Omalizumab Monoclonal Antibody Biosimilars by Application (2019-2030)
Figure 56. Global Omalizumab Monoclonal Antibody Biosimilars Price (USD/Unit) by Application (2019-2030)
Figure 57. Omalizumab Monoclonal Antibody Biosimilars Value Chain
Figure 58. Omalizumab Monoclonal Antibody Biosimilars Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
